Michael Wells
Henry Ford Health System
10 Papers
42 Citations
Michael Wells is an academic researcher from Henry Ford Health System. The author has contributed to research in topics: DNA methylation & Glioma. The author has an hindex of 5, co-authored 10 publications. Previous affiliations of Michael Wells include University of California, San Diego.
Chat about Author
Papers
A serum-based DNA methylation assay provides accurate detection of glioma.
Thais S. Sabedot,Tathiane M. Malta,James Snyder,Kevin Nelson,Michael Wells,Ana C. deCarvalho,Abir Mukherjee,Dhananjay Chitale,Maritza S Mosella,Artem Sokolov,Karam Asmaro,Adam M. Robin,Mark L. Rosenblum,Tom Mikkelsen,Jack Rock,Laila M. Poisson,Ian Lee,Tobias Walbert,Steven N. Kalkanis,Antonio Iavarone,Ana Valeria Castro,Houtan Noushmehr +21 more
TL;DR: The results suggest that the GeLB score can be used as a complementary approach to diagnose and follow up patients with glioma.
71
Needle biopsy under computerized tomographic control: a method for tissue diagnosis in intracranial lesions.
Hector E. James,Michael Wells,John F. Alksne,Ingmar Wickbom,Paul T. Siemers,Folke J. Brahme,Jay Rosenberg +6 more
TL;DR: Thirteen patients with intracranial lesions were submitted to a twist drill needle biopsy under computerized tomographic (CT) control, with sedation and local anesthesia, and definitive diagnosis was obtained in all but 2 patients with this technique.
18
Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers
Houtan Noushmehr,Thais S. Sabedot,Tathiane M. Malta,Kevin Nelson,James Snyder,Michael Wells,Ana C. deCarvalho,Abir Mukherjee,Dhananjay Chitale,Maritza S Mosella,Karam Asmaro,Adam M. Robin,M Rosenblum,T. Mikkelsen,Jack Rock,Laila M. Poisson,Ian Lee,Tobias Walbert,S. Kalkanis,Anavaleria Castro +19 more
TL;DR: Glioma-eLB can accurately predict a patient’s glioma from those with other neoplasias, non-neoplastic immunological conditions, and from healthy individuals (sensitivity: 98%; specificity: 99%).
11
DNA Methylation-based Signatures Classify Sporadic Pituitary Tumors According to Clinicopathological Features
Maritza S Mosella,Maritza S Mosella,Thais S. Sabedot,Tiago C. Silva,Tathiane M. Malta,Felipe Segato Dezem,Karam Asmaro,Michael Wells,Abir Mukherjee,Laila M. Poisson,James Snyder,Ana C. deCarvalho,Tobias Walbert,Todd Aho,Steven N. Kalkanis,Paula Conde Lamparelli Elias,Sonir Roberto Rauber Antonini,Jack Rock,Houtan Noushmehr,Houtan Noushmehr,Margaret de Castro,Ana Valeria Castro +21 more
TL;DR: In this paper, the authors identified and validated methylation signatures, mainly annotated in enhancer regions that distinguished Pituitary neuroendocrine tumors by distinct adenohypophyseal cell lineages and functional status.
10
DNA Methylation-based Signatures Classify Sporadic Pituitary Tumors According to Clinicopathological Features.
Maritza S Mosella,Maritza S Mosella,Thais S. Sabedot,Tiago C. Silva,Tathiane M. Malta,Felipe Segato,Karam Asmaro,Michael Wells,Abir Mukherjee,Laila M. Poisson,James Snyder,Ana C. deCarvalho,Tobias Walbert T,Todd Aho,Steven N. Kalkanis,Paula Conde Lamparelli Elias,Sonir Roberto Rauber Antonini,Jack Rock,Houtan Noushmehr,Houtan Noushmehr,Margaret de Castro,Ana Valeria Castro +21 more
TL;DR: This study identified and validated methylation signatures that distinguished pituitary tumors into molecular groups that reflect the functionality and adenohypophyseal cell lineages of these tumors, and demonstrated that methylome profiling provides an objective approach to classify PT.